<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000650</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 166</org_study_id>
    <secondary_id>11141</secondary_id>
    <nct_id>NCT00000650</nct_id>
  </id_info>
  <brief_title>An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients</brief_title>
  <official_title>An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Connaught Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine, in HIV-infected patients, the magnitude and duration of the biological effects&#xD;
      of ditiocarb sodium (sodium diethyldithiocarbamate; DTC) that may be relevant to treatment of&#xD;
      HIV infection.&#xD;
&#xD;
      DTC has been studied in previous clinical trials in HIV-infected patients with the suggestion&#xD;
      of delay in disease progression to AIDS and improvement in CD4 counts while on the drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DTC has been studied in previous clinical trials in HIV-infected patients with the suggestion&#xD;
      of delay in disease progression to AIDS and improvement in CD4 counts while on the drug.&#xD;
&#xD;
      Two groups of patients, one group asymptomatic and the other with AIDS diagnosis, are&#xD;
      enrolled in the study. All patients receive DTC intravenously once a week for two weeks.&#xD;
      Drugs are given on days 1 and 8. Blood samples are drawn on days 1, 3, 5, 8, 10, and 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 1996</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>12</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ditiocarb sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must:&#xD;
&#xD;
          -  Have HIV infection.&#xD;
&#xD;
          -  Be asymptomatic (group 1) or have AIDS (group 2).&#xD;
&#xD;
          -  Be able to understand and follow instructions.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        GROUP 2:&#xD;
&#xD;
          -  Anti-HIV therapy.&#xD;
&#xD;
          -  Systemic prophylaxis or maintenance therapy for any AIDS-defining opportunistic&#xD;
             infection excluding agents considered immunomodulators or immunosuppressants.&#xD;
&#xD;
          -  Topical nystatin.&#xD;
&#xD;
          -  Clotrimazole troches.&#xD;
&#xD;
          -  Acyclovir.&#xD;
&#xD;
          -  Dapsone.&#xD;
&#xD;
          -  Trimethoprim / sulfamethoxazole (T/S).&#xD;
&#xD;
          -  Fluconazole.&#xD;
&#xD;
          -  Ketoconazole.&#xD;
&#xD;
          -  Aerosolized pentamidine.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
        ALL PATIENTS:&#xD;
&#xD;
          -  Known hypersensitivity to disulfiram or diethyldithiocarbamate (DTC).&#xD;
&#xD;
          -  Transfusion dependence.&#xD;
&#xD;
        GROUP 1 PATIENTS ONLY:&#xD;
&#xD;
          -  Oral candidiasis documented by morphology or by a response to antifungal therapy.&#xD;
&#xD;
          -  Oral hairy leukoplakia.&#xD;
&#xD;
          -  Occurrence of herpes zoster in a single dermatomal distribution.&#xD;
&#xD;
          -  Recurrent seborrheic dermatitis.&#xD;
&#xD;
          -  Unintentional weight loss in excess of 10 pounds or 10 percent of usual body weight&#xD;
             within 2 years prior to study.&#xD;
&#xD;
          -  Unexplained temperature above 38 degrees C on more than 5 consecutive days or on more&#xD;
             than 10 days in any 30 days within 2 years of expected study entry.&#xD;
&#xD;
          -  Unexplained diarrhea defined by two or more stools/day for at least 14 days during a&#xD;
             120-day interval.&#xD;
&#xD;
          -  Evidence of clinically significant cardiac, respiratory, hepatic, gastrointestinal,&#xD;
             endocrine, hematologic, psychiatric, neurologic, renal, or dermatologic disease as&#xD;
             demonstrated by history, physical, and laboratory evaluation.&#xD;
&#xD;
        GROUP 2 PATIENTS ONLY:&#xD;
&#xD;
          -  Concurrent neoplasms other than Kaposi's sarcoma or basal cell carcinoma of the skin.&#xD;
&#xD;
          -  Diagnosis of an acute opportunistic infection within 3 weeks of study entry or had&#xD;
             treatment initiated for an opportunistic infection within 3 weeks of study entry.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        ALL PATIENTS:&#xD;
&#xD;
          -  Recombinant erythropoietin.&#xD;
&#xD;
        GROUP 1:&#xD;
&#xD;
          -  Antiretroviral medications.&#xD;
&#xD;
        GROUP 2:&#xD;
&#xD;
          -  Immunomodulators or immunosuppressants.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Requirement for blood transfusions more than once a month.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
        GROUP 1 PATIENTS ONLY:&#xD;
&#xD;
          -  Oral candidiasis documented by morphology or by a response to antifungal therapy.&#xD;
&#xD;
          -  Oral hairy leukoplakia.&#xD;
&#xD;
          -  Occurrence of herpes zoster in a single dermatomal distribution.&#xD;
&#xD;
          -  Recurrent seborrheic dermatitis.&#xD;
&#xD;
          -  Unintentional weight loss in excess of 10 pounds or 10 percent of usual body weight&#xD;
             within 2 years prior to study.&#xD;
&#xD;
          -  Unexplained temperature above 38 degrees C on more than 5 consecutive days or on more&#xD;
             than 10 days in any 30-day period within 2 years of expected study entry.&#xD;
&#xD;
          -  Unexplained diarrhea defined by two or more stools/day for at least 14 days during a&#xD;
             120-day interval.&#xD;
&#xD;
          -  Evidence of clinically significant cardiac, respiratory, hepatic, gastrointestinal,&#xD;
             endocrine, hematologic, psychiatric, neurologic, renal, or dermatologic disease as&#xD;
             demonstrated by history, physical, and laboratory evaluation.&#xD;
&#xD;
        GROUP 2 PATIENTS ONLY:&#xD;
&#xD;
          -  Diagnosis of an acute opportunistic infection within 3 weeks of study entry or had&#xD;
             treatment initiated for an opportunistic infection within 3 weeks of study entry.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        ALL PATIENTS:&#xD;
&#xD;
          -  Corticosteroids, cytotoxic agents, or immunomodulating agents within 30 days prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Chronic Antabuse (disulfiram) therapy.&#xD;
&#xD;
        GROUP 1 ONLY:&#xD;
&#xD;
          -  Antiretrovial medications within 1 week prior to study entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Transfusion within 7 days of study entry.&#xD;
&#xD;
          -  Radiation therapy within 30 days prior to study entry.&#xD;
&#xD;
        Unable to refrain from the use of alcohol for the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PS Lietman</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>P Barditch-Crovo</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Evaluation</keyword>
  <keyword>Ditiocarb</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ditiocarb</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

